PRT2527
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Arms / Cohorts
Experimental:PRT2527 Monotherapy in Lymphoid Malignancies
Accepting patients
Experimental:PRT2527/Zanubrutinib Combination in Lymphoid Malignancies
Accepting patients
Experimental:PRT2527 Monotherapy in Myeloid Malignancies
Accepting patients
Experimental:PRT2527/Venetoclax Combination in Myeloid Malignancies
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.